CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Income (Loss) from Equity Method Investments
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Income (Loss) from Equity Method Investments of $8.52 million for the 9-month period ending 2016-09-24, per its 10-Q filed 2016-11-02.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2016-11-02
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for the quarter ending 2016-09-24 was $442.00K, a 86.36% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for the quarter ending 2016-06-25 was $4.99M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for the quarter ending 2016-03-26 was $3.08M, a 142.49% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for the quarter ending 2015-12-26 was $219.00K, a 88.62% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for fiscal 2015 was $3.82M, a 58.90% decline from fiscal 2014.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for fiscal 2014 was $9.30M, a 58.61% increase from fiscal 2013.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for fiscal 2013 was $5.86M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income (loss) from equity method investments for fiscal 2012 was -$618.00K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2016-09-24 | $442.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $5.44M derived: sum of 2 quarters · filed 2016-11-02 | $8.52M 10-Q · filed 2016-11-02 | $8.74M derived: sum of 4 quarters · filed 2016-11-02 |
| 2016-06-25 | $4.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $8.08M 10-Q · filed 2016-08-03 | $8.29M derived: sum of 3 quarters · filed 2016-08-03 | $11.54M derived: sum of 4 quarters · filed 2016-08-03 |
| 2016-03-26 | $3.08M 10-Q · filed 2016-05-04 | $3.30M derived: sum of 2 quarters · filed 2016-05-04 | $6.54M derived: sum of 3 quarters · filed 2016-05-04 | $5.63M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-12-26 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $3.46M derived: sum of 2 quarters · filed 2016-02-12 | $2.55M derived: sum of 3 quarters · filed 2016-02-12 | $3.82M 10-K · filed 2016-02-12 |
| 2015-09-26 | $3.24M 10-Q · filed 2015-11-04 | $2.33M derived: sum of 2 quarters · filed 2015-11-04 | $3.60M 10-Q · filed 2016-11-02 | $5.53M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-06-27 | -$907.00K 10-Q · filed 2015-07-30 | $364.00K 10-Q · filed 2016-08-03 | $2.29M derived: sum of 3 quarters · filed 2016-05-04 | $1.49M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-03-28 | $1.27M 10-Q · filed 2016-05-04 | $3.19M derived: sum of 2 quarters · filed 2016-05-04 | $2.39M derived: sum of 3 quarters · filed 2016-05-04 | $4.47M derived: sum of 4 quarters · filed 2016-05-04 |
| 2014-12-27 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.12M derived: sum of 2 quarters · filed 2016-02-12 | $3.20M derived: sum of 3 quarters · filed 2016-02-12 | $9.30M 10-K · filed 2016-02-12 |
| 2014-09-27 | -$803.00K 10-Q · filed 2015-11-04 | $1.27M derived: sum of 2 quarters · filed 2015-11-04 | $7.38M 10-Q · filed 2015-11-04 | $8.41M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-28 | $2.08M 10-Q · filed 2015-07-30 | $8.18M 10-Q · filed 2015-07-30 | $9.21M derived: sum of 3 quarters · filed 2016-02-12 | $12.74M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-29 | $6.10M 10-Q · filed 2015-04-30 | $7.14M derived: sum of 2 quarters · filed 2016-02-12 | $10.66M derived: sum of 3 quarters · filed 2016-02-12 | $12.06M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-28 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $4.56M derived: sum of 2 quarters · filed 2016-02-12 | $5.95M derived: sum of 3 quarters · filed 2016-02-12 | $5.86M 10-K · filed 2016-02-12 |
| 2013-09-28 | $3.53M 10-Q · filed 2014-10-30 | $4.92M derived: sum of 2 quarters · filed 2014-10-30 | $4.83M 10-Q · filed 2014-10-30 | |
| 2013-06-29 | $1.40M 10-Q · filed 2014-08-07 | $1.30M 10-Q · filed 2014-08-07 | ||
| 2013-03-30 | -$90.00K 10-Q · filed 2014-04-30 | |||
| 2012-12-29 | -$618.00K 10-K · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |